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Abstract
Asthma is one of the most prevalent chronic inflammatory 
lung disease among children and adults. Morbidity and 
mortality rate of asthma is raising at the rate of 10% 
every year inspite of availability of contemperory modern 
medicines. Studies show that presently majority of world 
population are using complementory and altenative 
medicines for the management of bronchial asthma. 
Ayurveda (Indian system of medicine) is the most popular 
and widely used alternative medicine. Extensive and 
proficient researches in the field of Ayurveda validate its 
efficay in the mangement of chronic diseases including 
asthma. The present study was designed to search a safe 
and effective herbal medicine for the treatment of acute 
attack of Bronchial Asthma and secondary objective to 
expand the sphere of Ayurvedic medicine by exploring 
the new possibilities of drug administration techniques.
Hydroethanolic extract of both the polyherbal compounds 
were given through nebulization and their efficacy was 
assessed. Results showed that all groups treated with 
Ayurvedic compounds had significant improvent in PFT 
(pulmonary function test). Cough, Expectoration and ESR 
is markedly reduced in group treaed with Bharangyadi 
Ayurvedic Nebulizer whereas Wheezing, frequency of 
attack and severity of attack on exposure to allergens was 
significantly (p < 0.001) reduced in group treated with 
Shirishadi Ayurvedic Nebulizer.
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INTRODUCTION
The human respiratory tract is universally exposed to air 
pollution and rapidly changing atmospheric conditions 
(Tripathi, 1998). The care for the respiratory tract should 
be stressed more often nowadays, especially in view of 
a dramatic increase in the incidence of life-threatening 
diseases like asthma (Vishwanath, et al., 1966). There is a 
noticeable increase in health care burden from asthma in 
several areas of the world (World Allergy Organization, 
2011). The increasing mortality rates and hospitalization 
related to asthma are a major cause of concern for 
physician (World Health Organization Bronchial Asthma, 
2005). Contemperory modern medicine proves its efficacy 
in the management of Broncial asthma but the wide 
range of toxic side effects and increasing resistance to 
antiboiotics compell to search some better alternative 
(World Health Organization, 2007). Ayurvedic system of 
medicine continues to be the best alternative care available 
for the majority of the global population. Plants constitute 
the centre-piece of therapy in this system of medicine for 
restoring or maintaining the well-being of the people. In 
the present trial we choose two polyherbal compounds 
namely Shirishadi and Bharangyadi, and assess their 
anti-asthmatic property with respect to contemperory 
modern medicine. The drugs were decided to given throug 
nasal route via nebulization machine.Nasal route of drug 
administration was decided as there are several plus points 
for the through-the-lung delivery of medication. The 
lungs have a large surface area, so that absorption is fast 
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and ample. Lungs are much more permeable than skin, 
nasal mucosa or the gastro-intestinal tract. Moreover 
in Ayurveda Nasya (administration of drug through 
nasal route) is said to be best for ailment related to 
Pranavaha Srotasa (respiratory tract). 
1.  MATERIAL & METHODS
Table 1
Trial Drug’s Content of Shirishyadi Ayurvedic Nebulizer
Name of the drug Botonical name Part uesd Approx. quantity in 100ml of extract
Shirisha Albezzia lebbeck Twaka (Bark) 20 mg
Nagarmotha Cyprus rotundus Kanda (Rhizome) 20 mg
Kantkari Solanum xanthocarpum Panchanga (Whole plant) 20 mg
Table 2
Trial Drug’s Content of Bharangyadi Ayurvedic Nebulizer 
Name of the drug Botonical name Part uesd Approx. quantity in 100ml of extract
Bharangi Clerodendrum serratum Moola ( Root) 20 mg
Sati Hedychium spicatum Moola (Root) 20 mg
Pushkarmoola Inula racemosa Moola (Root) 20 mg
The plants were collected from local market of Varanasi. 
The identification of the drugs was done by Prof.
A.K.Singh, Department of Dravyaguna, S.S.U.,Varanasi 
(Identification number DG/AKS/604). Hydroalcoholic 
Extraction (Distilled water: Ethanol = 2:1) of drugs was 
carried out by Hot percolation method through soxhlet 
apparatus. Thereafter extracts were dried using rotatory 
evaporator and dried extracts was put to the process of 
standardization.
1.1  Drug Schedule
1.1.1  Ayurvedic Nebulization Drug
Extract given through nebulization: 2.5 ml (1 mg/
ml) extract of Shirishyadi & Bharangyadi (1 mg/ml) 
compound were given through nebulization twice in a day 
for 15 days and then S.O.S in group I & II whereas 3 ml 
extract of Shirisha-Bharangyadi extract twice in a day 
were given in Shirishabharangyadi Group (Group III).
1.1.2  Ayurvedic Oral Drug 
Shirishyadi & Bharangyadi Ghana Vati in the dose of 
500 mg, twice in a day with luke warm water for one 
month given in follow-up patients of Group I & II. 
Shirishabharangyadi Ghana Vati—500 mg, twice in a day 
with the anupana of ushnodaka was given in follow-up 
patients of Group-III.
1.1.3  Modern Medication
Duoline (Levosalbutamol + Ipratropium bromide) 2 mg 
twice in a day in one group and 2 mg of Budecort twice in 
a day in another group for 15 days and then S.O.S. Oral 
modern Drug: Tab Deiphyllin retard (115 + 35 mg), twice 
in a day for 15 days and then S.O.S.
1.1.4  Placebo Therapy 
Group V asthmatic patients were put on placebo treatment. 
2.5 ml of normal saline was given twice in a day for 15 
days and Sugar pills (inert placebo tablets) in a dose of 
one tablet twice in a day for 15 days.
During trial patient posing any serious complications 
or side effects were immediately discontinued and shifted 
on modern medicaments.In placebo controlled group only 
mild asthmatic patient with no side effect were choosen to 
avoid any discomfort for the patients and following ethical 
guidelines for biomedical research directed by ICMR .
1.2  Clinical Trial
Human Trial consist of Phase 0 Clinical Study, Phase I 
Clinical Study, and Phase II Clinical Study.
For the assessment of drug safety, efficacy and 
determination of drug dose. 
1.2.1  Phase 0 Clinical Study
For this study four healthy individual were selected and 
divided into two groups.
100 microliters of water extract (prepared through 
decoction method) of Bharangyadi mixture (Bharangyadi 
Ayurvedic Nebulizer) dissolved in 1.5 ml of distilled water 
in B.D. doses had been given to two healthy individual 
for 5 days. Routine blood test, Renal function test,& Liver 
function test was done before and after administration of 
drug.
Similarly 100 microliters of water extract (prepared 
through decoction method) of Shirishyadi mixture 
(Shirishyadi Ayurvedic Nebulizer) dissolved in 1.5 ml 
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of distilled water in B.D. doses had been given to two 
healthy individual for 5 days. Routine blood test, Renal 
function test,& Liver function test was done before and 
after administration of drug.
No toxic side effect has been reported. Pharmacodynamic 
& Pharmacokinetic study will be done latter.
1.2.2  Phase I Clinical Study
Multiple Ascending Dose Determination Study:
Ten patients (well diagnosed Case of Bronchial Asthma) 
were selected for this study and divided into two groups.
Five patients were allocated in Bharangyadi Ayurvedic 
Nebulizer Group and Five patients were allocated in 
Shirishadi Ayurvedic Nebulizer Group and the drug was 
given in following ascending doses:
100 microliters of extract dissolved in 1.5 ml of 
distilled water B.D. for 2 days.
200 microliters extract dissolved in 1.5 ml of distilled 
water B.D. for 2 days.
400 microliters extract dissolved in 1.5 ml of distilled 
water B.D. for 2 days.
600 microliters extract dissolved in 1.5 ml of distilled 
water B.D. for 2 days.
800 microliters extract dissolved in 1.5 ml of distilled 
water B.D. for 2 days.
1000 microliters extract dissolved in 1.5 ml of distilled 
water B.D. for 2 days.
Followed by Routine Blood, Renal function and Liver 
function test. Spirometery and lung X ray was also done.
Dose Determination of Drug:
On the basis of Phase I Clinical study the dose of 
Drugs were decide as 5 mg/daily in two divided doses.
This study was mainly carried out to determine the dose 
of drugs so no statistical analysis of data had been done.
The study showed that drugs were safe for human trial 
and no toxic side effect had been reported during the trial.
No pathophysiological improvement was noted in 
pulmonary function test and chest Xray.
As drugs were proved safe for human trial it was 
further proceed for Phase II Clinical testing.
1.2.3  Phase-II Clinical Study 
Selection of Cases: O.P.D./I.P.D. wing of Department of 
Kayachikitsa S.S.Hospital, B.H.U.
Age: 18-60 years 
Sample Size: A total number of 100 cases will be 
included in the proposed clinical trial.
Exclusion Criteria: 
Bronchial Carcinoma
Emphysema
Chronic Pulmonary Obstructive Disease
Pleural Effusion
Tuberculosis
Cardiac Asthma
Status Asthmatics
Design-Randomized study 
2.  STUDY GROUPS
For this study 100 clinically diagnosed and confirmed 
patients of Bronchial Asthma were randomly divided into 
five groups:
Group I: 20 registered patients of Bronchial Asthma 
were administered “Shirishadi Ayurvedic Nebulizer” 2.5 
mg (2.5 ml) twice in a day for first 15 days and then S.O.S, 
followed by oral administration of Shirishadi Ghana Vati 
-500 mg with luke warm water, twice in a day for one 
month. 
Group II: 20 registered patients of Bronchial Asthma 
were administered “Bharangiadi Ayurvedic Nebulizer” 2.5 
mg (2.5 ml) twice in a day for first 15 days and then S.O.S, 
followed by oral administration of Shirishadi Ghana Vati 
-500 mg with luke warm water, twice in a day for one 
month.
Group III: 20 registered patients of Bronchial Asthma 
were administered “Shirishbharangyadi Ayurvedic 
Nebulizer” 3 mg (3 ml) twice in a day for first 15 days and 
then S.O.S, followed by oral administration of Shirishadi 
Ghana Vati -500 mg with luke warm water, twice in a day 
for one month. 
Group IV: 20 registered patients of Bronchial Asthma 
divided into two groups {each group consist of 10 
patient’s} and were given Duoline (Levosalbutamol + 
Ipratropium bromide) 2 mg twice in a day in one group 
and 2 mg of Buddecort twice in a day in another group for 
15 days followed by oral administration of tab Deiphyllin 
retard (115 + 35 mg), twice in a day for 15 days and then 
s.o.s.
Group V: 20 registered patients of Bronchial Asthma 
will be administered 2.5 ml normal saline twice in a day 
for 15 days.
3.  FOLLOW-UP STUDIES
All the patients of three groups were regularly follow up 
once after 15 day for 1 and 1/2 month.
Improvement and other effects were noted down.
All the patients were asked to undergo laboratory 
investigations before and after the treatment and during 
follow-ups.
Duration of Trial: 45 days
Duration of Nebulization: 15 days
Duration of Oral treatment: 30 days
Total duration of treatment: 45 days.
4.  OBSERVATIONS AND RESULTS
Drop out Analysis: Total 20: 1 cases in G1, 2 cases in G2, 
3 cases in G3, 4 cases in G4 and 10 cases in G5.
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Table 3
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Dyspnea in Bronchial Asthma
Groups Symptomsgrading
Dyspnea
Number of patients Within the groups comparison 
friedman test
BT AT F1 F2
Group I
Mild 0 0 1 (5.3%) 1 (5.3%)
χ2 = 34.9
p < 0.001
Moderate 6 (31.6%) 13 (68.4%) 14 (73.7%) 14 (73.7%)
Severe 8 (42.4%) 5 (26.3%) 3 ( 15.8%) 3 ( 15.8%)
Agonizing 5 (26.3%) 1 (5.3%) 1( 5.3%) 1( 5.3%)
Group II
Mild 1 (5.3%) 2 (10.5%) 2 (10.5%) 3 (15.6%)
χ2 = 53.34
p < 0.001
Moderate 6 (31.6%) 11 (57.9%) 11 (57.9%) 10 (52.6%)
Severe 8 (42.4%) 4 (21.1%) 6 (31.6%) 6 (31.6%)
Agonizing 4 (21.1%) 2 (10.5%) 0 0
Group III
Mild 0 3 (16.7%) 2 (11.1%) 2 (11.1%)
χ2 = 34.9
p < 0.001
Moderate 7 (38.9%) 12 (66.7%) 13 (72.2%) 13 (72.2%)
Severe 7 (38.9%) 3 (16.7%) 3 (16.7%) 3 (16.7%)
Agonizing 4 (22.2%) 0 0 0
Group IV
Mild 0 5 (31.3%) 5 (31.3%) 5 (31.3%)
χ2 = 48.0
p < 0.001
Moderate 6 (37.5%) 11 (68.8%) 11 (68.8%) 11 (68.8%)
Severe 7(43.8%) 0 0 0
Agonizing 3(18.8%) 0 0 0
GroupV
Mild 1 (10.0%) 0 0 0
χ2 = 4.00
p = 0.26
p > 0.05
Moderate 8 (80.0%) 2 (20.0%) 2 (20.0%) 2 (20.0%)
Severe 1 (10.0%) 7 (70.0%) 7 (70.0%) 8 (80.0%)
Agonizing 0 1 (10.0%) 1 (10.0%) 0
Between the Group 
comparison χ2 Test
χ2 = 10.7
p < 0 .05
df = 4
χ2 = 21.0
p < 0 .001
df = 4
χ2 = 22.4
p < 0 .001
df = 4
χ2 = 22.40
p < 0 .001
df = 4
     _
Table 4
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Cough in Bronchial Asthma
Groups Symptomsgrading
Cough
Number of patients Within the groups comparison 
friedman test
BT AT F1 F2
Group I
Absent 0 3 (15.8%) 4 (21.1%) 4 (21.1%)
χ2 = 42.48
p < 0.001
Mild 3 (15.8%) 10 (52.6%) 9 (47.4%) 9 (47.4%)
Moderate 9 (47.4%) 4 (21.1%) 4 ( 21.1%) 3 ( 15.8%)
Severe 7 (36.8%) 2 (10.5%) 2( 10.5%) 3 ( 15.8%)
Group II
Absent 1 (5.3%) 5 (26.3%) 6 (31.6%) 6 (31.6%)
χ2 = 49.62
p < 0.001
Mild 3 (15.8%) 11 (57.9%) 10 (52.6%) 10 (52.6%)
Moderate 11 (57.9%) 3(15.8%) 3 (15.8%) 3 (15.8%)
Severe 4 (21.1%) 0 0 0
To be continued
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Groups Symptomsgrading
Cough
Number of patients Within the groups comparison 
friedman test
BT AT F1 F2
Group III
Absent 1 (5.6%) 7 (38.9%) 8 (44.4%) 8 (44.4%)
χ2 = 49.62
p < 0.001
Mild 2 (11.1%) 9 (50.0%) 8 (44.4%) 8 (44.4%)
Moderate 10 (55.6%) 2 (11.1%) 2 (11.1%) 2 (11.1%)
Severe 5 (27.8%) 0 0 0
Group IV
Absent 1(6.3%) 8(50.0%) 9(56.3%) 9(56.3%)
χ2 = 43.64
p < 0.001
Mild 1 (6.3%) 7 (43.8%) 6 (37.5%) 6 (37.5%)
Moderate 9 (56.3%) 1 (6.3%) 1(6.3%) 1(6.3%)
Severe 5(31.3%) 0 0 0
GroupV
Absent 0 0 0 0
χ2 = 4.38
p = 0.223
Mild 2 (20.0%) 2 (20.0%) 2 (20.0%) 3 (30.0%)
Moderate 8 (80.0%) 6 (60.0%) 8 (80.0%) 7 (70.0%)
Severe 0 2 (20.0%) 0 0
Between the Group 
comparison χ2 Test
χ2 = 1.73
p > 0 .05
df = 4
χ2 = 10.2
p < 0 .05
df = 4
χ2 = 11.2
p < 0 .05
df = 4
χ2 = 11.2
p < 0 .05
df = 4
     _
Table 5
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Expectoration in Bronchial Asthma
Groups SymptomsGrading
Expectoration
Number of patients Within the Groups comparison 
Friedman Test
BT AT F1 F2
Group I
Absent 3 (15.8%) 9(47.4%) 10 (55.6%) 10 (52.6%)
χ2 = 27.38
p < 0.001
Mild 11 (57.9%) 8 (42.1%) 6 (33.3%) 7 (36.8%)
Moderate 4(21.1%) 3 (10.5%) 2 ( 11.1%) 2 ( 10.5%)
Severe 1 (5.3%) 0 0 0
Group II
Absent 0 5 (26.3%) 5 (26.3%) 6 (31.6%)
χ2 = 55.61
p < 0.001
Mild 3 (15.8%) 13 (68.4%) 13 (68.4%) 12 (63.2%)
Moderate 8 (42.1%) 1(5.3%) 1 (5.3%) 1 (5.3%)
Severe 8 (42.1%) 0 0 0
Group III
Absent 0 6 (33.3%) 6 (33.3%) 7 (38.9%)
χ2 = 52.62
p < 0.001
Mild 2 (11.1%) 11(61.1%) 11(61.1%) 10 (55.6%)
Moderate 8 (44.4%) 1 (5.6%) 1 (5.6%) 1(5.6%)
Severe 8 (44.4%) 0 0 0
Group IV
Absent 0 7 (43.8%) 7 (43.8%) 8(50.0%)
χ2 = 46.63
p < 0.001
Mild 1 (6.3%) 8(50.0%) 8(50.0%) 7 (43.8%)
Moderate 7 (43.8%) 1 (6.3%) 1 (6.3%) 1 (6.3%)
Severe 8(50.0%) 0 0 0
GroupV
Absent 0 0 0 0
χ2 = 9.00
p = 0.029
Mild 4 (40.0%) 2 (20.0%) 3 (30.0%) 3 (30.0%)
Moderate 6 (60.0%) 6 (60.0%) 7 (70.0%) 7 (70.0%)
Severe 0 2 (20.0%) 0 0
Between the Group 
comparison χ2 Test
χ2 = 10.3
p < 0 .05
df = 4
χ2 = 6.94
p > 0 .05
df = 4
χ2 = 9.25
p > 0 .05
df = 4
χ2 = 9.19
p > 0 .05
df = 4
     _          
Continued
6Copyright © Canadian Research & Development Center of Sciences and Cultures
Antiasthmatic Effect of Standardized Extract of Ayurvedic Compounds 
via Nasal Spray Actuation (in Aerosol Form) in Rodents and Its 
Comparative Clinical Study
Table 6
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Wheezing in Bronchial Asthma
Groups SymptomsGrading
Wheezing
Number of patients Within the Groups comparison 
Friedman Test
BT AT F1 F2
Group I
Absent 3 (15.8%) 9(47.4%) 10 (55.6%) 10 (52.6%)
χ2 = 48.0
p < 0.001
Mild 11 (57.9%) 8 (42.1%) 6 (33.3%) 7 (36.8%)
Moderate 4(21.1%) 2 (10.5%) 2 ( 11.1%) 2 ( 10.5%)
Severe 1 (5.3%) 0 0 0
Group II
Absent 0 5 (26.3%) 5 (26.3%) 6 (31.6%)
χ2 = 54.15
p < 0.001
Mild 3 (15.8%) 13 (68.4%) 13 (68.4%) 12 (63.2%)
Moderate 8 (42.1%) 1(5.3%) 1 (5.3%) 1 (5.3%)
Severe 8 (42.1%) 0 0 0
Group III
Absent 0 6 (33.3%) 6 (33.3%) 7 (38.9%)
χ2 = 51.15
p < 0.001
Mild 2 (11.1%) 11(61.1%) 11(61.1%) 10 (55.6%)
Moderate 8 (44.4%) 1 (5.6%) 1 (5.6%) 1(5.6%)
Severe 8 (44.4%) 0 0 0
Group IV
Absent 0 0 0 0
χ2 = 45.17
p < 0.001
Mild 1 (6.3%) 7 (43.8%) 7 (43.8%) 8(50.0%)
Moderate 7 (43.8%) 8(50.0%) 8(50.0%) 7 (43.8%)
Severe 8(50.0%) 1 (6.3%) 1 (6.3%) 1 (6.3%)
GroupV
Absent 0 0 0 0
χ2 = 6.00
p < 0.112
Mild 4 (40.0%) 2 (20.0%) 3 (30.0%) 3 (30.0%)
Moderate 6 (60.0%) 6 (60.0%) 7 (70.0%) 7 (70.0%)
Severe 0 2 (20.0%) 0 0
Between the Group 
comparison χ2 Test
χ2 = 10.9
p > 0 .05
df = 4
χ2 = 13.8
p < 0 .01
df = 4
χ2 = 16.8
p < 0 .01
df = 4
χ2 = 17.0
p < 0.01
df = 4        _
Table 7
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Pinasa(Rhinorrhoea) in Bronchial 
Asthma
Groups SymptomsGrading
Pinasa
Number of patients
Within the Groups 
comparison Friedman 
TestBT AT F1 F2
Group I
Absent 3 (15.8%) 8 (92.1%) 9 (47.4%) 12 (63.2%)
χ2 = 40.84
p < 0.001
Mild 1 (5.3%) 9 (47.4%) 9(47.4%) 6 (31.6%)
Moderate 9(47.4%) 2 (10.5%) 1 (5.3%) 1 ( 5.3%)
Severe 6 (31.6%) 0 0 0
Group II
Absent 0 8 (42.1%) 9 (47.4%) 12 (63.2%)
χ2 = 55.61
p < 0.001
Mild 5 (26.3%) 11(57.9%) 9 (47.4%) 6 (31.6%)
Moderate 6 (31.6%) 0 1 (5.3%) 1 (5.3%)
Severe 8 (42.1%) 0 0 0
Group III
Absent 0 10 (55.6%) 10 (55.6%) 11 (61.1%)
χ2 = 52.62
p < 0.000
Mild 4 (22.2%) 8 (44.4%) 8 (44.4%) 7 (38.9%)
Moderate 6 (33.3%) 0 0 0
Severe 8 (44.4%) 0 0 0
Group IV
Absent 0 9 (56.3%) 9 (56.3%) 11 (68.8%)
χ2 = 45.52
p < 0.001
Mild 3 (18.8%) 7 (43.8%) 7 (43.8%) 5 (31.3%)
Moderate 6 (37.5%) 0 0 0
Severe 7(43.8%) 0 0 0
To be continued
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Groups SymptomsGrading
Pinasa
Number of patients
Within the Groups 
comparison Friedman 
TestBT AT F1 F2
Group V
Absent 2 (20.0%) 2(20.0%) 2(20.0%) 2 (20.0%)
χ2 = 4.71
p < 0.194
Mild 3 (30.0%) 3 (30.0%) 3 (30.0%) 4 (40.0%)
Moderate 5 (50.0%) 4 (40.0%) 4 (40.0%) 4 (40.0%)
Severe 0 1 (10.0%) 1 (10.0%) 0
Between the Groups 
comparison χ2 Test
χ2 = 9.93
p < 0 .05
df = 4
χ2 = 4.28
p > 0 .05
df = 4
χ2 = 3.99
p > 0.05
df = 4
χ2 = 7.19
p > 0.05
df = 4
Table 8
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Urahshoola (Pain in chest region) in 
Bronchial Asthma
Groups SymptomsGrading
Urahshoola
Number of patients Within the Groups 
comparison Friedman Test
BT AT F1 F2
Group I
Absent 12 (63.2%) 17(89.5%) 18 (94.7%) 19 (100%)
χ2 = 15.81
p = .001
Mild 7(36.8%) 2 (10.5%) 1 (5.3%) 0
Moderate 0 0 0 0
Severe 0 0 0 0
Group II
Absent 5(26.3%) 15 (78.9%) 15 (78.9%) 19 (100%)
χ2 = 36.22
p < 0.001
Mild 8 (42.1%) 4 (21.1%) 4 (21.1%) 0
Moderate 6 (31.6%) 0 0 0
Severe 0 0 0 0
Group III
Absent 4(22.2%) 15 (83.3%) 15 (83.3%) 18 (100%)
χ2 = 36.66
p < 0.001
Mild 7 (38.9%) 3 (16.7%) 3 (16.7%) 0
Moderate 7 (38.9%) 0 0 0
Severe 0 0 0 0
Group IV
Absent 3 (18.8%) 13 (81.3%) 13 (81.3%) 16(100%)
χ2 = 33.78
p < 0.001
Mild 6 (37.5%) 3 (18.8%) 3 (18.8%) 0
Moderate 7 (43.8%) 0 0 0
Severe 0 0 0 0
Group V
Absent 5 (50.0%) 6 (60.0%) 6 (60.0%) 6 (60.0%)
χ2 = 3.00
p = 0.392
Mild 5 (50.0%) 4 (40.0%) 4 (40.0%) 4 (40.0%)
Moderate 0 0 0 0
Severe 0 0 0 0
Between the Group 
comparison χ2 Test
χ2 = 11.3
p < 0 .05
df = 4
χ2 = 3.78
p > 0 .05
df = 4
N.S.
χ2 = 5.44
p > 0 .05
df = 4
N.S.
χ2 = 30.3
p > 0.001
df = 4
N.S.
     _
Table 9
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Frequency of Attack in Bronchial Asthma
Groups SymptomsGrading
Frequency of Attack
Number of patients
Within the Groups 
comparison Friedman 
TestBT AT F1 F2
Group I
Absent 0 5 (26.3%) 5 (26.3%) 5 (26.3%)
χ2 = 53.48
p < 0.001
Mild 5 (26.3%) 11 (57.9%) 11 (57.9%) 14 (73.7%)
Moderate 4 (21.1%) 3 (15.8%) 3 (15.8%) 0
Severe 10 (52.6%) 0 0 0
Group II
Absent 0 4 (21.1%) 4 (21.1%) 4 (21.1%)
χ2 = 49.72
p < 0.001
Mild 5 (26.3%) 15 (78.9%) 15 (78.9%) 15 (78.9%)
Moderate 8 (42.1%) 0 0 0
Severe 6 (31.6%) 0 0 0
Continued
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Groups SymptomsGrading
Frequency of Attack
Number of patients
Within the Groups 
comparison Friedman 
TestBT AT F1 F2
Group III
Absent 0 7 (38.9%) 7 (38.9%) 7 (38.9%)
χ2 = 46.73
p < 0.001
Mild 4 (22.2%) 11 (61.1%) 11 (61.1%) 11 (61.1%)
Moderate 8 (44.4%) 0 0 0
Severe 6 (33.3%) 0 0 0
Group IV
Absent 0 9 (56.3%) 9 (56.3%) 9 (56.3%)
χ2 = 40.76
p < 0.001
Mild 3 (18.8%) 7 (43.8%) 7 (43.8%) 7 (43.8%)
Moderate 7 (43.8%) 0 0 0
Severe 6 (37.5%) 0 0 0
Group V
Absent 0 0 0 0
χ2 = 6.00
p = 0.112
Mild 5 (50.0%) 4 (40.0%) 4 (40.0%) 4 (40.0%)
Moderate 5 (50.0%) 6 (60.0%) 6 (60.0%) 6 (60.0%)
Severe 0 0 0 0
Between the Group 
comparison χ2 Test
χ2 = 3.47
p > 0 .05
df = 4
χ2 = 11.0
p < 0 .05
df = 4
χ2 = 11.0
p < 0 .05
df = 4
χ2 = 11.0
p < 0 .05
df = 4       _
Table 10
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Orthopnea in Bronchial Asthma
Groups SymptomsGrading
Orthopnea
Number of patients Within the Groups comparison 
Friedman Test
BT AT F1 F2
Group I
Absent 6 (31.6%) 10 (52.6%) 10 (52.6%) 10 (52.6%)
χ2 = 39.00
p < 0.001
Mild 4 (21.1%) 9 (47.4%) 9 (47.4%) 9 (47.4%)
Moderate 9 (47.4%) 0 0 0
Severe 0 0 0 0
Group II
Absent 4 (21.1%) 9 (47.4%) 10 (52.6%) 11 (57.9%)
χ2 = 39.50
p < 0.001
Mild 6 (31.6%) 10 (52.6%) 9 (47.4%) 8(42.1%)
Moderate 9 (47.4%) 0 0 0
Severe 0 0 0 0
Group III
Absent 4(22.2%) 13 (72.2%) 13 (72.2%) 13 (72.2%)
χ2 = 39.00
p < 0.001
Mild 8 (44.4%) 5 (27.8%) 5 (27.8%) 5 (27.8%)
Moderate 6 (33.3%) 0 0 0
Severe 0 0 0 0
Group IV
Absent 3 (18.8%) 15 (93.8%) 15 (93.8%) 15 (93.8%)
χ2 = 36.00
p < 0.001
Mild 7 (43.8%) 1 (6.3%) 1 (6.3%) 1 (6.3%)
Moderate 6 (37.5%) 0 0 0
Severe 0 0 0 0
Group V
Absent 4 (40.0%) 0 5(50.0%) 5 (50.0%)
χ2 = 3.66
p < 0.300
Mild 6 (60.0%) 5 (50.0%) 5 (50.0%) 5 (50.0%)
Moderate 0 4 (40.0%) 0 0
Severe 0 1 (10.0%) 0 0
Between the Group 
comparison χ2 Test
χ2 = 2.15
p > 0.05
df = 4
N.S.
χ2 = 24.7
p < 0.001
df = 4
χ2 = 9.72
p < 0.05
df = 4
χ2 = 8.99
p > 0.05
df = 4
N.S.
Table 11
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Fever in Bronchial Asthma
Groups SymptomsGrading
Fever
Number of patients Within the Groups 
comparison Friedman Test
BT AT F1 F2
Group I
Absent 7 (36.8%) 16 (84.2%) 17 (89.5%) 17 (89.5%)
χ2 = 34.68
p < 0.001
Mild 4 (21.1%) 3 (15.8%) 2 (10.5%) 2 (10.5%)
Moderate 8 (42.1%) 0 0 0
Severe 0 0 0 0
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To be continued
9 Copyright © Canadian Research & Development Center of Sciences and Cultures
Kajaria Divya.; Tripathi, J. S.; Samaria, J. K.; Tiwari, S. K. (2013). 
Advances in Natural Science, 6(3), 1-13
Groups SymptomsGrading
Fever
Number of patients Within the Groups 
comparison Friedman Test
BT AT F1 F2
Group II
Absent 9 (47.4%) 17 (89.5%) 17 (89.5%) 17 (89.5%)
χ2 = 30.00
p < 0.001
Mild 7 (36.8%) 2 (10.5%) 2 (10.5%) 2 (10.5%)
Moderate 3 (15.8%) 0 0 0
Severe 0 0 0 0
Group III
Absent 8(44.4%) 16 (88.9%) 16 (88.9%) 16 (88.9%)
χ2 = 30.00
p < 0.001
Mild 7 (38.9%) 2 (11.1%) 2 (11.1%) 2 (11.1%)
Moderate 3 (16.7%) 0 0 0
Severe 0 0 0 0
Group IV
Absent 6 (37.5%) 14 (87.5%) 14 (87.5%) 14 (87.5%)
χ2 = 30.00
p < 0.001
Mild 7 (43.8%) 2 ( 12.5%) 2 ( 12.5%) 2 ( 12.5%)
Moderate 3 (18.8%) 0 0 0
Severe 0 0 0 0
Group V
Absent 6 (60.0%) 7 (70.0%) 7(70.0%) 7(70.0%)
χ2 = 3.00
p = 0.392
Mild 4 (40.0%) 3 (30.0%) 3 (30.0%) 3(30.0%)
Moderate 0 0 0 0
Severe 0 0 0 0
Between the Group 
comparison χ2 Test
χ2 = 47.5
p < 0 .001
df = 4
χ2 = 2.40
p > 0.05
df = 4
χ2 = 2.73
p > 0.05
df = 4
χ2 = 2.73
p > 0.05
df = 4       _
Table 12
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Paroxysms of dyspnea in Bronchial Asthma
Groups SymptomsGrading
Paroxysms of dyspnea
Number of patients Within the Groups 
comparison Friedman Test
BT AT F1 F2
Group I
Absent 0 16 (84.2%) 17 (89.5%) 17 (89.5%)
χ2 = 52.90
p < 0.001
Mild 0 3 (15.8%) 2 (10.5%) 2 (10.5%)
Moderate 5 (26.3%) 0 0 0
Severe 14 (73.7%) 0 0 0
Group II
Absent 0 2 (10.5%) 2 (10.5%) 3 (15.8%)
χ2 = 54.37
p < 0.001
Mild 0 15 (78.9%) 16 (84.2%) 15 (78.9%)
Moderate 8 (42.1%) 2 (10.5%) 1 (5.3%) 1 (5.3%)
Severe 11 (57.9%) 0 0 0
Group III
Absent 0 6 (33.3%) 6 (33.3%) 6 (33.3%)
χ2 = 54.00
p < 0.001
Mild 0 12 (66.7%) 12 (66.7%) 12 (66.7%)
Moderate 8 (44.4%) 0 0 0
Severe 10 (55.6%) 0 0 0
Group IV
Absent 0 10 (62.5%) 10 (62.5%) 6 (37.5%)
χ2 = 44.00
p < 0.001
Mild 0 6 ( 37.5%) 6 ( 37.5%) 8 (50.0%)
Moderate 8 (50.0%) 0 0 2 (12.5%)
Severe 8 (50.0%) 0 0 0
Group V
Absent 0 2 (20.0%) 0 0
χ2 = 6.00
p = 0.112
Mild 5 (50.0%) 5 (50.0%) 7 (70.0%) 7(70.0%)
Moderate 3 (30.0%) 3 (30.0%) 3 (30.0%) 3 (30.0%)
Severe 2 (20.0%) 0 0 0
Between the Group 
comparison χ2 Test
χ2 = 0.00
p > 0.05
df = 4
χ2 = 26.5
p < 0.001
df = 4
χ2 = 28.3
p < 0.001
df = 4
χ2 = 31.3
p < 0.001
df = 4       _
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Table 13
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Duration of Vega/attack in Bronchial Asthma
Groups SymptomsGrading
Duration of Vega/attack
Number of patients
Within the Groups 
comparison Friedman 
TestBT AT F1 F2
Group I
Absent 0 2 (10.5%) 2 (10.5%) 2 (10.5%)
χ2 = 55.61
p < 0.001
Mild 0 15 (78.9%) 15 (78.9%) 16 (84.2%)
Moderate 8 (42.1%) 2 (10.5%) 2 (10.5%) 1 (5.3%)
Severe 11 (57.9%) 0 0 0
Group II
Absent 0 4 (21.1%) 4 (21.1%) 5 (26.3%)
χ2 = 52.42
p < 0.001
Mild 4 (21.1%) 12 (63.2%) 14 (73.7%) 14 (73.7%)
Moderate 6 (31.6%) 3 (15.8%) 1 (5.3%) 0
Severe 9 (47.4%) 0 0 0
Group III
Absent 0 6 (33.3%) 6 (33.3%) 7 (38.9%)
χ2 = 51.39
p < 0.001
Mild 3 (16.7%) 11 (61.1%) 12 (66.7%) 11 (61.1%)
Moderate 6 (33.3%) 1 (5.6%) 0 0
Severe 9 (50.0%) 0 0 0
Group IV
Absent 0 13 (81.3%) 6 (37.5%) 3 (18.8%)
χ2 = 42.21
p < 0.001
Mild 1 (6.3%) 3 (18.8%) 10 (62.5%) 13 (81.3%)
Moderate 7 (43.8%) 0 0 0
Severe 8 (50.0%) 0 0 0
Group V
Absent 1 (10.0%) 2 (20.0%) 2 (20.0%) 2 (20.0%)
χ2 = 1.20
p = 0.753
Mild 5 (50.0%) 3 (30.0%) 4 (40.0%) 4(40.0%)
Moderate 4 (40.0%) 5 (50.0%) 4 (40.0%) 4 (40.0%)
Severe 0 0 0 0
Between the Group 
comparison χ2 Test
χ2 = 7.29
p > 0.05
df = 4
χ2 = 23.2
p < 0.001
df = 4
χ2 = 4.47
p > 0.05
df = 4
χ2 = 4.54
p > 0.05
df = 4      _
Table 14
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on Eosinophil Count in Bronchial Asthma
Groups
Eosinophil count
Mean + S.D. Within the group comparison paired t test
BT AT F1 F2 BT-AT BT-F1 AT-F1 BT-F2 AT-F2
Group I 5.3+4.1 3.5+1.8 4.5+ 1.7 3.2+ 1.1
1.84+3.3
t = 2.38
p < 0.05
1.31+4.0
t = 1.40
p > 0.05
0.52+1.9
t = 1.17
p > 0.05
2.10+3.8
t = 2.51
p < 0.05
0.26+1.4
t = 0.81
p > 0.05
Group II 5.6+4.9 4.3+2.9 4.0+2.6 4.2+4.5
1.31+3.1
t = 1.81
p > 0.05
1.62+3.1
t = 2.27
p < 0.05
0.31+1.0
t = 1.37
p > 0.05
1.36+6.3
t = 0.94
p > 0.05
0.05+4.8
t = 0.047
p > 0.05
Group III 6.8+4.1
4.2+
2.7
4.0+
2.6 4.2+4.5
2.55+2.7
t = 3.9
p < 0.001
2.77+2.5
t = 4.6
p < 0.001
0.22+0.9
t = 1.0
p > 0.05
2.61+5.5
t = 2.01
p > 0.05
0.05+4.9
t = 0.04
p > 0.05
Group IV 3.7+2.1
2.9+
2.8
2.3+
2.2 2.1+2.3
0.81+2.6
t = 1.2
p > 0.05
1.43+2.4
t = 2.3
p < 0.05
0.62+0.8
t = 3.10
p > 0.001
1.62+2.5
t = 2.60
p < 0.05
0.81+0.9
t = 3.10
p > .001
Group V 3.6+ 1.8 9.5+3.4 9.4+ 1.5 8.9+1.8
5.90+3.4
t = 5.7
p < 0.001
5.81+1.9
t = 9.9
p < 0.001
5.27+2.0
t = 8.72
p < 0.001
0.009+2.4
t = 0.12
p > 0.05
0.63+2.6
t = 0.806
p > 0.05
Between the Group 
comparison One 
Way ANOVA
F = 1.9
P > 0.05
F = 
11.18
P < 
0.001
F = 17.37
P < 0.001
F = 7.42
P < 0.001
Post Hoc Test 
Significant 
Pairs (P < .05) None
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
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Table 15
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on ESR in Bronchial Asthma
Groups
ESR
Mean + S.D. Within the group comparison paired t test
BT AT F1 F2 BT-AT BT-F1 AT-F1 BT-F2 AT-F2
Group I 20.8+9.4 12.8+6.5 14.8+4.9 16.7+4.5
7.9+9.0
t = 3.83
p < 0.001
5.94+8.1
t = 3.17
p < 0.001
4.10+
7.8
t = 2.2
p < 0.05
2.00+
3.4
t = -2.52
p < 0.05
3.84+
4.96
t = 3.37
p < 0.001
Group II 24.5+6.9 17.3+6.7 16.7+6.2 16.9+5.4
7.26+4.6
t = 6.82
p < 0.001
7.84+4.5
t = 7.4
p < 0.001
7.63+5.2
t = 6.3
p < 0.001
0.57+
2.83
t = 0.89
p > 0.05
0.36+
4.03
t = 0.398
p > 0.05
Group III 25.0+6.9 17.3+6.8 16.8+6.4 17.3+5.3
7.6+4.13
t = 7.81
p < 0.001
8.11+4.36
t = 7.88
p < 0.001
7.66+4.8
t = 6.7
p < 0.001
0.500+2.7
t = 0.76
p > 0.05
0.005+
3.4
t = 0.068
p > 0.05
Group IV 20.3+6.9 15.3+5.8 15.5+6.12
15.3+
5.6
4.9 +3.8
t = 5.14
p < 0.001
4.8+3.7
t = 5.09
p < 0.001
5.00 +
3.75
t = 5.32
p < 0.001
0.12+
2.4
t = -0.20
p > 0.05
0.006+
3.12
t = 0.08
p > 0.05
Group V 21.0+6.0 27.7+6.2 25.5+5.1 24.0+5.3
6.7+2.5
t = -8.3
p < 0.001
4.5+3.8
t = -3.7
p < 0.005
3.00+
4.69
t = 2.02
p > 0.05
2.20+
4.07
t = 1.7
p > 0.05
3.7+3.9
t = 2.94
p < 0.05
Between 
the Group 
comparison 
One Way 
ANOVA
F = 1.53
P > 0.05
F = 8.90
P < 0.001
F = 6.11
P < 0.001
F = 4.62
P > 0.001
Post Hoc Test 
Significant 
Pairs (P < .05)
None
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
Table 16
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on PEFR (Peak Expiratory Flow Rate) in 
Bronchial Asthma
Groups
PEFR
Mean + S.D. Within the group comparison paired t test
BT AT F1 F2 BT-AT BT-F1 AT-F1 BT-F2 AT-F2
Group I 120+38.0 210+69.6
207+
65.6
197+
61.8
90+
58.4
t = 6.71
p < 0.001
87.3+
54.9
t = 6.92
p < 0.001
77.6+
49.7
t = 6.80
p < 0.001
2.63+
9.3
t = 1.22
p > 0.05
12.3+
13.3
t = 4.03
p < 0.001
Group II 132+80.9 200+78.7 195+80
185+
76.5
67.7+
48.6
t = 6.0
p < 0.001
62.6+
47.8
t = 5.70
p < 0.001
5.2+
12.1
t = 1.88
p > 0.05
52+
46
t = 4.89
p < 0.001
15.2+
12.18
t = 5.45
p < 0.001
Group III 118+55.3 210+74.9 198.8+ 81.3 189.4+77.4
91.6+
53.7
t = 7.24
p < 0.001
80+56
t = -6.04
p < 0.001
11.1+
10.7
t = 4.37
p < 0.001
71.1+
53.4
t = -5.6
p < 0.001
20.5+
11.6
t = 7.50
p < 0.001
Group IV 138+72.2 194+80.0
141+
60.7
138+
58.1
55.6+
29.6
t = 7.50
p < 0.001
3.12+
31.9
t = 0.39
p > 0.05
52.51+32.76
t = 6.41
p < 0.001
0.62+
24.3
t = 0.10
p > 0.05
56.2+
32.0
t = 7.02
p < 0.001
Group V 141.0+44.3 134+48.9 134+48.8
131+
43.8
6.5+10.5
t = 1.94
p > 0.05
7.0+
9.48
t = 2.33
p < 0.05
0.50+
6.85
t = 0.23
p > 0.05
10.0+
11.54
t = 2.73
p < 0.05
3.50+
14.5
t = 0.761
p > 0.05
Between the Group 
comparison One 
Way ANOVA
F = 0.44
P > 0.05
F = 2.12
P = > 0.05
F = 3.50
P = < 0.05
F = 3.15
P < 0.05
Post Hoc Test 
Significant 
Pairs (P < .05) None None
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
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Table 17
Comparative Clinical Study of Shirishadi & Bharangyadi Compounds on FVC (Forced Vital Capacity) in 
Bronchial Asthma
Groups
FVC
Mean + S.D. Within the group comparison paired t test
BT AT F1 F2 BT-AT BT-F1 AT-F1 BT-F2 AT-F2
Group I 1.55+0.53 2.16+0.55 2.17+0.49
2.18+
0.50
0.60+
0.44
t = 5.90
p < 0.001
10.3+
42.1
t = 1.06
p > 0.05
9.70+
42.2
t = 1.00
p > 0.05
0.62+
0.55
t = 4.90
p < 0.001
0.0016+
0.27
t = 0.25
p > 0.05
Group II 1.30+0.82 2.29+0.90 2.21+0.80
2.11+
0.77
0.91+
0.78
t = 5.60
p < 0.001
0.91+
0.75
t = 5.32
p < 0.001
0.0072+0.29
t = 1.06
p > 0.05
0.81+
0.68
t = 5.15
p < 0.001
0.17+
0.31
t = 2.43
p < 0.05
Group III 1.21+0.78 2.43+0.72 2.25+0.68
2.16+
0.62
1.20+
0.58
t = 8.80
p < 0.001
1.04+
0.62
t = 7.08
p < 0.001
0.17+
0.28
t = 2.60
p < 0.05
0.95+
0.55
t = 7.20
p < 0.001
0.27+
0.29
t = 3.86
p < 0.001
Group IV 1.18+0.75 2.10+0.80 1.49+0.71
1.54+
0.73
0.92+
0.32
t = 11.4
p < 0.001
0.31+
0.47
t = 2.50
p < 0.05
0.61+
0.43
t = 5.71
p < 0.001
0.36+
0.42
t = 3.4
p < 0.001
0.56+
0.35
t = 6.26
p < 0.001
Group V 1.07+0.53 1.03+0.48 1.04+0.43
1.02+
0.45
0.003+
0.13
t = 0.914
p > 0.05
2.70+
0.16
t = 0.50
p > 0.05
0.001+ 7.47
t = -0.46
p > 0.05
0.004+ 0.17
t = 0.79
p > 0.05
0.0006+9.7
t = 0.194
p > 0.05
Between 
the Group 
comparison One 
Way ANOVA
F = 1.00
P > 0.05
F = 6.63
P < 0.001
F = 0.88
P = < 0.001
F = 8.01
P < 0.001
Post Hoc Test 
Significant Pairs 
(P < .05)
None
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
Table 18
Comparative Clinical Study of Shirishadi & Bharangyadi compounds on FEV1 (Forced Expiratory Volume) in 
Bronchial Asthma
Groups
FEV1
Mean + S.D. Within the group comparison paired t test
BT AT F1 F2 BT-AT BT-F1 AT-F1 BT-F2 AT-F2
Group I 1.45+ 0.60 2.09+ 0.61 2.06+0.63
1.9+
0.60
0.61+
0.48
t = 5.50
p < 0.001
0.58+
0.50
t = 5.00
p < 0.001
0.003+
0.12
t = 1.17
p > 0.05
0.50+
0.50
t = 4.38
p < 0.001
0.10+
0.12
t = 3.79
p < 0.001
Group II 1.01+ 0.51 1.50+ 0.60 1.50+0.55
1.45+
0.54
0.54+
0.39
t = 6.00
p < 0.001
0.49+
0.39
t = 5.03
p < 0.001
0.005+ 0.12
t = 1.90
p > 0.05
4.38+
0.38
t = 5.03
p < 0.001
0.17+
0.11
t = 4.27
p < 0.001
Group III 0.98+ 0.51 1.6+ 0.51 1.58+0.44
1.60+
0.41
0.68+
0.40
t = 7.3
p < 0.001
0.60+
0.43
t = 5.8
p < 0.001
0.008+
0.18
t = 2.09
p > 0.05
0.61+
0.40
t = 6.48
p < 0.001
0.007+
0.17
t = 1.77
p > 0.05
Group IV 1.13+ 0.42 1.60+ 0.57 1.36+0.49
1.40+
0.47
0.46+
0.31
t = 5.9
p < 0.001
0.22+
0.31
t = 2.8
p < 0.01
0.24+
0.30
t = 3.13
p < 0.001
0.26+
0.21
t = 3.5
p < 0.001
0.20+
0.26
t = 3.07
p < 0.001
Group V 1.14+ 0.51 1.10+ 0.49 1.09+0.54
1.16+
0.42
0.003+
0.009
t = 1.2
p > 0.05
0.004+
0.22
t = 0.62
p > 0.05
0.002+0.14
t = -0.62
p > 0.05
0.0009+0.21
t = 0.13
p > 0.05
0.006+0.14
t = 1.36
p > 0.05
Between the Group 
comparison One 
Way ANOVA
F = 2.39
P > 0.05
F = 5.31
P < 0.001
F = 6.50
P = < 0.001
F = 5.49
P < 0.001
Post Hoc Test 
Significant 
Pairs (P < .05)
None
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
(1,5)
(2,5)
(3,5)
(4,5)
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5.  DISCUSSION
The clinical study was conducted on 100 patients suffering 
from Bronchial Asthma out of which twenty patients were 
dropped out. The selections of the patients were strictly 
based on reversibility test. 
The clinical studies on subjective, objective and 
laboratory parameters have revealed that patients 
treated with ‘Duoline and Budecort Nebulizer had 
shown significant improvement initially but after 
prolonged use the progress become constant along with 
the drug dependence. Moreover patients treated with 
Budecort showed some side effects such as leg cramps, 
dizziness, palpitation, acidity and nervousness. The most 
striking fact observed in patients treated with modern 
medicine was high rate of recurrence in symptoms. 
After completion of the course of medicine patient gets 
the symptom of disease reappeared within 10-15 days. 
Moreover no improvement was observed in recurrence of 
attack on exposure to allergens. In the patients of B.A., 
treated with “Ayurvedic Nebulizer” statistically significant 
improvement on various parameters was recorded after 
the course of the therapy. The patients showed faster 
relief in symptoms with no apparent toxic effects. The 
improvement in pulmonary function remained constant 
even after 1 month of discontinuation of drugs i.e. there 
was no rebound broncho-constriction. There was more 
than 20% improvement in PEER, measured just after the 
administration of drug.
All the three groups treated with Ayurvedic medicines 
were showed significant improvement in PFT evidenced 
by marked increase in FEV1, FVC & PEFR. As there 
was no significant change found in patients treated 
with normal saline it can be said the effect produced 
by Ayurvedic drugs were existent and not apparent or 
placebo effect. Reduction in ESR & Eosinophil count was 
more prominent when the drugs were given through oral 
route than nasal administration of drugs, suggesting that 
systemic effect of the drugs were more effective when 
given through oral route.
The clinical study depict that there is strong relation 
between mental health and incidence of Tamaka Shwasa. 
Stress was major causative factor in provoking attack of 
asthma in female patients mainly housewife’s who had 
complained of their husband ignorance and thus showed 
relief even treatment with normal saline whereas there 
was no improvement found in PFT.
One patient treated with Bharangyadi Ayurvedic 
Nebulizer showed marked increase in Eosinophil count 
after 1 week of treatment, the patient was discontinued 
from the trial and put on modern medicine. No other 
patient showed such increase in Eosinophil count. Except 
this the overall result of drug is good in controlling the 
breathlessness.
The patient treated with “Shirishadi Ayurvedic 
Nebulizer” showed no recurrence of asthmatic attack 
on exposure to allergens (dust, pollen grain etc) after 
treatment. This showed that drug is able to disrupt the 
pathogenesis of disease from its origin, and this clinically 
confirm the relation between Ama and Allergy.
Administration of drug through nasal route shows 
quick action, as the drug directly acts on Pranavaha 
Srotas. Drugs given through this route increase Rasagni 
and reduces Rasagata Kapha thereby clearing the passage 
of Pranavayu which is clinically proved by increase in 
PEFR, decrease in ESR, & expulsion of sputum.
Clinical study revealed that Shirishabharangyadi 
has more potent antiasthmatic effect than Shirishadi and 
Bharangyadi compound as improvement were quicker 
in this group with least relapses and uniform consistency 
throughout follow-ups.
CONCLUSION
It  can be concluded that Polyherbal compounds 
Shirishabharangyadi, Shirishadi and Bharangyadi have 
potent antiasthmatic activity with maximum potency of 
Shirishabharangyadi followed by Shirishadi. It can be 
further concluded that these Polyherbal compounds can 
be used as “Therapeutic Agents” in the management 
of acute attack of Asthma as well as chronic persistent 
Asthma. The trial gives a direction for searching new 
route of herbal drug administration. In spite of limitations 
the present study conducted entirely from new angle. The 
study has yielded several useful observations & result 
which would definitely open new vistas for the future 
research workers of Ayurveda in general and respiratory 
disorders as particular.
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